HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (416)	9/30/2002 9:21:51 PM
From: Miljenko Zuanic	Read Replies (1) of 1022

"If you're trying to produce anything anti-human, there are very simple serology lessons that scream "avoid MEDX and ABGX". " Rick, please can you be bit more specific, in plain language? It is true that so far CATG have more candidates (seven) in clinic than ABGX (five). CATG is older company than ABGX ('96 versus '98) with 100 billions antibodies in library. Many predicted that time to move hmAb candidate trough preclinical development phase will be much shorter than for small molecules (1-2 years versus 3-5 years). Seems that it is not a case. What you see as main problem(s)? Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next